NUVB Stock Analysis: Nuvation Bio | NYSE
Biotechnology | NYSE, USA | Market Cap: 2.015m USD | 12M Return: 74.5% | US67080N1019 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 27.2M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 6.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Nuvation Bio Inc. (NYSE: NUVB) is a U.S.-based, clinical-stage biopharmaceutical company founded in 2018 and headquartered in New York, focused on developing oncology product candidates. Its lead asset, IBTROZI (taletrectinib), is a ROS1 inhibitor for patients with ROS1-positive non-small cell lung cancer (NSCLC). The company is also advancing Safusidenib, a mutant IDH1 inhibitor currently in Phase 3 trials as a maintenance therapy for high-risk IDH1-mutant astrocytoma. Nuvation went public in August 2020 and operates as a small-cap biotechnology company within the Health Care sector.
As a clinical-stage biotech, Nuvation does not yet generate meaningful product revenue and relies on capital markets and potential partnerships to fund its research and development pipeline. The companys focus on genetically defined oncology targets, such as ROS1 and IDH1 mutations, reflects a broader industry shift toward precision medicine and biomarker-driven cancer therapies.
- IBTROZI sales accelerate following ROS1+ NSCLC commercial launch
- Safusidenib Phase 3 data for IDH1 astrocytoma looms as catalyst
- Repotrectinib approval intensifies ROS1 inhibitor competition for IBTROZI
| Net Income: -149.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 37.74 > 1.0 |
| NWC/Revenue: 376.5% < 20% (prev 3.88k%; Δ -3.50k% < -1%) |
| CFO/TA -0.11 > 3% & CFO -82.6m > Net Income -149.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (348.8m) vs 12m ago 2.35% < -2% |
| Gross Margin: 93.94% > 18% (prev 27.54%; Δ 66.39% > 0.5%) |
| Asset Turnover: 24.42% > 50% (prev 2.22%; Δ 22.20% > 0%) |
| Interest Coverage Ratio: -4.84 > 6 (EBIT TTM -129.2m / Interest Expense TTM 26.7m) |
| A: 0.86 (Total Current Assets 726.4m - Total Current Liabilities 86.8m) / Total Assets 744.5m |
| B: -1.58 (Retained Earnings -1.17b / Total Assets 744.5m) |
| C: -0.19 (EBIT TTM -129.2m / Avg Total Assets 695.9m) |
| D: 0.52 (Book Value of Equity 253.9m / Total Liabilities 490.6m) |
| Altman-Z'' = -0.20 = B |
| DSRI: 0.40 (Receivables 31.7m/6.68m, Revenue 169.9m/14.4m) |
| GMI: 0.29 (GM 27.54% / 93.94%) |
| AQI: 0.65 (AQ_t 0.02 / AQ_t-1 0.03) |
| SGI: 11.84 (Revenue 169.9m / 14.4m) |
| TATA: -0.09 (NI -149.8m - CFO -82.6m) / TA 744.5m) |
| Beneish M = 3.40 (Cap -4..+1) = D |
As of September 30, 2026, the stock is trading at USD 5.62 with a total of 3,067,906 shares traded. Over the past week, the price has changed by -7.87%, over one month by -15.62%, over three months by +0.18% and over the past year by +74.53%.
Current recommended Stop Loss: 5.10 (which is 9.3% or 1.7 ATR below the current price).
Nuvation Bio has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy NUVB.
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 13.1 | 133.1% |
P/S = 11.8626
P/B = 8.437
Revenue TTM = 169.9m USD
EBIT TTM = -129.2m USD
EBITDA TTM = -127.0m USD
Long Term Debt = 242.6m USD (from longTermDebt, last quarter)
Short Term Debt = 7.61m USD (from shortTermDebt, last quarter)
Debt = 255.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.62m
Net Debt = -250.2m USD (calculated: Debt 255.8m - CCE 506.0m)
Enterprise Value = 1.77b USD (2.02b + Debt 255.8m - CCE 506.0m)
Interest Coverage Ratio = -4.84 (Ebit TTM -129.2m / Interest Expense TTM 26.7m)
EV/FCF = 19.29x (Enterprise Value 1.77b / FCF TTM 91.5m)
FCF Yield = 5.18% (FCF TTM 91.5m / Enterprise Value 1.77b)
FCF Margin = 53.85% (FCF TTM 91.5m / Revenue TTM 169.9m)
Net Margin = -88.19% (Net Income TTM -149.8m / Revenue TTM 169.9m)
Gross Margin = 93.94% ((Revenue TTM 169.9m - Cost of Revenue TTM 10.3m) / Revenue TTM)
Gross Margin QoQ = none% (prev 93.25%)
Tobins Q-Ratio = 2.37 (Enterprise Value 1.77b / Total Assets 744.5m)
Interest Expense / Debt = 10.43% (Interest Expense 26.7m / Debt 255.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -102.1m (EBIT -129.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.35 (Total Current Assets 726.4m / Total Current Liabilities 98.8m)
Debt / Equity = 1.01 (Debt 255.8m / totalStockholderEquity, last quarter 253.9m)
Debt / EBITDA = 1.97 (negative EBITDA) (Net Debt -250.2m / EBITDA -127.0m)
Debt / FCF = -2.74 (Net Debt -250.2m / FCF TTM 91.5m)
Total Stockholder Equity = 301.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -21.53% (Net Income -149.8m / Total Assets 744.5m)
RoE = -49.73% (Net Income TTM -149.8m / Total Stockholder Equity 301.3m)
RoCE = -23.75% (EBIT -129.2m / Capital Employed (Equity 301.3m + L.T.Debt 242.6m))
RoIC = -15.54% (negative operating profit) (NOPAT -102.1m / Invested Capital 656.9m)
WACC = 9.01% (E(2.02b)/V(2.27b) * Re(9.11%) + D(255.8m)/V(2.27b) * Rd(10.43%) * (1-Tc(0.21)))
Discount Rate = 9.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.39 | Cagr: 22.96%
[DCF] Terminal Value 73.14% ; FCFF base≈91.5m ; Y1≈91.9m ; Y5≈97.3m
[DCF] Fair Price = 4.60 (EV 1.36b - Net Debt -250.2m = Equity 1.61b / Shares 350.1m; r=9.01% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.66 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.09 | Chg30d=+18.18% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.29 | Chg30d=-3.57% | Revisions=-25% | GrowthEPS=+41.3% | GrowthRev=+212.9%
EPS next Year (2027-12-31): EPS=-0.01 | Chg30d=+75.00% | Revisions=-25% | GrowthEPS=+94.8% | GrowthRev=+41.7%
[Analyst] Revisions Ratio: -50% (up=0, down=3)